PL3505157T3 - Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie - Google Patents

Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie

Info

Publication number
PL3505157T3
PL3505157T3 PL17461651T PL17461651T PL3505157T3 PL 3505157 T3 PL3505157 T3 PL 3505157T3 PL 17461651 T PL17461651 T PL 17461651T PL 17461651 T PL17461651 T PL 17461651T PL 3505157 T3 PL3505157 T3 PL 3505157T3
Authority
PL
Poland
Prior art keywords
treatment
dry powder
pulmonary administration
resistant depression
ketamine composition
Prior art date
Application number
PL17461651T
Other languages
English (en)
Inventor
Maciej Wieczorek
Ewa TRATKIEWICZ
Przemysław Perko
Original Assignee
Celon Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma S.A. filed Critical Celon Pharma S.A.
Publication of PL3505157T3 publication Critical patent/PL3505157T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL17461651T 2017-12-29 2017-12-29 Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie PL3505157T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17461651.6A EP3505157B1 (en) 2017-12-29 2017-12-29 Dry powder ketamine composition for pulmonary administration in treatment-resistant depression

Publications (1)

Publication Number Publication Date
PL3505157T3 true PL3505157T3 (pl) 2022-04-11

Family

ID=60915417

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17461651T PL3505157T3 (pl) 2017-12-29 2017-12-29 Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
PL18773471T PL3731815T3 (pl) 2017-12-29 2018-09-28 Kompozycja ketaminy w postaci suchego proszku do zastosowania w leczeniu depresji przez podawanie dopłucne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18773471T PL3731815T3 (pl) 2017-12-29 2018-09-28 Kompozycja ketaminy w postaci suchego proszku do zastosowania w leczeniu depresji przez podawanie dopłucne

Country Status (16)

Country Link
US (1) US20200337999A1 (pl)
EP (2) EP3505157B1 (pl)
JP (1) JP7315556B2 (pl)
KR (1) KR20200105857A (pl)
CN (1) CN111818912A (pl)
AU (1) AU2018395791A1 (pl)
BR (1) BR112020013282A2 (pl)
CA (1) CA3087090A1 (pl)
DK (2) DK3505157T3 (pl)
EA (1) EA202091618A1 (pl)
ES (2) ES2907692T3 (pl)
HU (2) HUE058320T2 (pl)
MX (1) MX2020006900A (pl)
PL (2) PL3505157T3 (pl)
PT (2) PT3505157T (pl)
WO (1) WO2019129397A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628313A1 (en) * 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814790B1 (en) * 1995-02-24 2003-07-16 Stuart L. Weg Administration of ketamine for detoxification
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
AU2003291037A1 (en) * 2002-11-18 2004-06-15 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
WO2007111880A2 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
ME03465B (me) 2013-03-15 2020-01-20 Janssen Pharmaceutica Nv Farmaceutska kompozicija s-ketamin hidrohlorida
EP2968122B1 (en) 2013-03-15 2019-08-28 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
JP6473738B2 (ja) * 2013-04-01 2019-02-20 パルマトリックス,インコーポレイテッド チオトロピウム乾燥粉末
WO2016057712A1 (en) * 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
EP3628313A1 (en) * 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Also Published As

Publication number Publication date
CN111818912A (zh) 2020-10-23
EP3505157A1 (en) 2019-07-03
ES2907692T3 (es) 2022-04-26
PT3731815T (pt) 2022-02-15
DK3731815T3 (da) 2022-02-28
MX2020006900A (es) 2020-11-09
EP3505157B1 (en) 2021-12-08
PT3505157T (pt) 2022-02-18
EA202091618A1 (ru) 2021-03-17
BR112020013282A2 (pt) 2020-12-01
HUE058099T2 (hu) 2022-07-28
EP3731815A1 (en) 2020-11-04
EP3731815B1 (en) 2021-12-08
JP2021510682A (ja) 2021-04-30
US20200337999A1 (en) 2020-10-29
DK3505157T3 (da) 2022-02-28
AU2018395791A1 (en) 2020-07-16
WO2019129397A1 (en) 2019-07-04
ES2907781T3 (es) 2022-04-26
HUE058320T2 (hu) 2022-07-28
KR20200105857A (ko) 2020-09-09
JP7315556B2 (ja) 2023-07-26
PL3731815T3 (pl) 2022-04-11
CA3087090A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
IL272220B2 (en) Preparations in the form of dry powder to be administered into the nose
HK1258955A1 (zh) 干粉吸入器
IL255007A0 (en) Partial-dose dry powder inhalers
IL255008A0 (en) Dry powder inhaler with double resistance
SI3347472T1 (sl) Sestavki, ki obsegajo polipeptide klada CYP76AD1, in uporabe le-teh
SG11201708541QA (en) Dry powder composition comprising long-chain rna
SG11201708540VA (en) Dry powder composition comprising long-chain rna
ZA201602461B (en) Powder coating composition
PT3328215T (pt) Composições probióticas estáveis secas para utilizações dietéticas especiais
HK1256041A1 (zh) 乾粉吸入器
GB2548278B (en) Dry powder blending
IL263365A (en) Dry powder inhaler
GB2527336B (en) Sunscreen composition in powder form
ITUA20162751A1 (it) Composizione secca in polvere
PL3138601T3 (pl) Inhalator suchego proszku
GB2536305B (en) Dry shampoo composition
IL251665A0 (en) Dry powder formulation
ZA201800243B (en) Applicator, in particular rotary atomizer
IL249774A0 (en) Dry powder nebulizer
HUE058320T2 (hu) Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
PL3064555T3 (pl) Termoutwardzalna proszkowa kompozycja powłokowa
GB2542283B (en) Dry powder fire-fighting composition
GB2540454B (en) In vacuo coating compositions
EP3560492C0 (en) COMPOSITION OF LIPID PARTICLES AND PHARMACEUTICAL COMPOSITION
HK1254670A1 (zh) 曲普坦粉末用於肺部給藥